Rob Dillard

DocwireNews

Recently, global biopharmaceutical company UCB expanded its collaboration with tech giant Microsoft to accelerate the development of individualized medicines. DocWire News spoke with Herman De Prins, UCB&rsquo;s Chief Information Officer, to learn more about this partnership and its significance.&nbsp;DocWire News: Can you discuss UCB&rsquo;s collaboration with Microsoft and its significance?Herman De Prins: It&rsquo;s all about data and artificial intelligence. Basically, our partnership is about three things: the artificial intelligence technology, so technology cells that Microsoft brings in; the cloud computing and the capabilities there; and the third piece is their expertise on the technology.DocWire News: Can you discuss some of the work UCB and Microsoft have already done related to COVID-19?Herman De Prins:&nbsp;COVID-19 was a special one. We were collaborating in an open source collaboration around finding molecules to, let&rsquo;s say, defeat COVID-19. In that effort, we saw an opportunity to use Microsoft&rsquo;s cloud computing at scale.And so what we did is something that&rsquo;s not super new in terms of techniques. It&rsquo;s called molecular dynamics. What that does is it looks at how molecules interact with each other. But it requires huge compute power, so we reached out to Microsoft and said, &ldquo;Can we massively use your cloud environment, because we have that technology in-house too, but not that performance?&rdquo;And in a nutshell, we processed that initial effort in three days, which normally would take us six months. We used the compute power in different geographies in the world simultaneously to come up with these calculations.DocWire News: How important has artificial intelligence become in the development of new, individualized medicines?Herman De Prins: I think it&rsquo;s very important. If you think about the development process of a medicine, first of all, it&rsquo;s long. It&rsquo;s complex. It has many facets. But in each of these facets, there&rsquo;s an opportunity for artificial intelligence because you can combine diverse sets of data and learn from the data, look at correlations in ways that a human without machines and AI couldn&rsquo;t do. And so suddenly, for each of these steps in the process, you have faster and better insights on what&rsquo;s going on.DocWire News: What&rsquo;s the ultimate goal of UCB&rsquo;s collaboration with Microsoft?Herman De Prins: Where this fits is in what we call our patient value strategy. It&rsquo;s finding the right medicine for the right patient population in a faster way. And you do that in many ways through this collaboration. One is by the fact that you are able to generate insights faster. You can, for instance, identify potential targets faster, and look at potential candidates to address the target. Those molecules, you can then develop faster, et cetera, et cetera. So speed is an important element.The second element is what you could summarize in terms of quality. If you understand the patient journey better, if you understand the disease pathology better, you can target your efforts towards a higher probability of success.That also includes speed, of course, because you have the right patient population you choose and you have the right clinical protocol and you have the right everything. It&rsquo;ll be faster. But besides faster, the likelihood of having better outcomes for patients is much higher.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Herman De Prins, Chief Information Officer at UCB, Talks Collaboration with Microsoft to Accelerate Drug Development

Recently, global biopharmaceutical company UCB expanded its collaboration with tech giant Microsoft to accelerate the development of individualized medicines. DocWire News ...

Herman De Prins, Chief Information Officer at UCB, Talks Collaboration with Microsoft to Accelerate

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe